secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0000950170-21-004087
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones
--------------------------------------------------------------------------------

- XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.
- Approval and pre-launch milestones from partners expected to provide $19M non-dilutive funding, extending cash runway into 2023.
- Q3 2021 net loss $4.9M ($0.08 per share) vs $2.4M ($0.05 per share) in Q3 2020; revenue $3.1M vs $3.4M.
- Cash and cash equivalents $25.2M as of Sep 30, 2021.
- Phase 1/2a OASIS trial of CLS-AX (axitinib) in wet AMD completed dosing in Cohort 2; safety data expected by end of 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/0000950170-21-004087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/clsd-20211110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer